Overview Safety and Pharmacokinetics of NM6603 in Chinese Patients With Advanced Solid Tumors Status: NOT_YET_RECRUITING Trial end date: 2026-11-01 Target enrollment: Participant gender: Summary This study is to assess the MTD and PK of NM6603 in adult patients with advanced solid tumors.Phase: PHASE1 Details Lead Sponsor: NucMito Pharmaceuticals Co. Ltd.